EnteroMedics Announces Proposed Public Offering of Common Stock and Warrants

EnteroMedics Announces Proposed Public Offering of Common Stock and Warrants 
ST. PAUL, MN -- (Marketwire) -- 02/21/13 --  EnteroMedics Inc.,
(NASDAQ: ETRM), the developer of medical devices using neuroblocking
technology to treat obesity, metabolic diseases and other
gastrointestinal disorders, today announced its intention to offer,
subject to market and other conditions, shares of its common stock
and warrants to purchase common stock in an underwritten public
offering. The Company currently intends to use the net proceeds from
this offering to continue work toward regulatory approval of the
Maestro(R) RC System in the United States, for international
commercialization efforts, for clinical and product development
activities and for other working capital and general corporate
purposes. The offering is expected to price before 9:30 a.m. EDT on
February 22, 2013. 
Craig-Hallum Capital Group LLC is acting as the sole book-running
manager for the offering. 
The Company intends to offer and sell these securities pursuant to
the Company's existing shelf registration statement (File No.
333-183313), which was declared effective by the Securities and
Exchange Commission on August 29, 2012. A prospectus supplement
describing the terms of the offering will be filed with the
Securities and Exchange Commission and will form a part of the
effective registration statement. When available, copies of the
preliminary prospectus supplement, the final prospectus supplement
and the accompanying base prospectus related to this offering may be
obtained from the Securities and Exchange Commission's website at
http://www.sec.gov or by contacting Craig-Hallum Capital Group, LLC,
222 South Ninth Street, Suite 350, Minneapolis, MN 55402, by calling
612-334-6300, or by emailing bart.federak@craig-hallum.com. 
This press release does not constitute an offer to sell or the
solicitation of offers to buy any securities of the Company, and
shall not constitute an offer, solicitation or sale of any security
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. 
About VBLOC(R) Therapy 
EnteroMedics developed VBLOC(R) vagal blocking therapy to offer
bariatric surgeons and their patients a less invasive alternative to
existing surgical weight loss procedures that may present significant
risks and alter digestive system anatomy, lifestyle and food choices.
VBLOC(R) Therapy is delivered via the Maestro(R) System through
laparoscopically implanted leads to intermittently block the vagus
nerves using high-frequency, low-energy electrical impulses. VBLOC(R)
Therapy is designed to target the multiple digestive functions under
control of the vagus nerves and to affect the perception of hunger
and fullness. 
About EnteroMedics Inc.  
EnteroMedics is a medical device company focused on the development
and commercialization of its neuroscience based technology to treat
obesity and metabolic diseases. EnteroMedics' proprietary technology,
VBLOC(R) vagal blocking therapy, delivered by a pacemaker-like device
called the Maestro(R) Rechargeable System, is designed to
intermittently block the vagus nerves using high-frequency,
low-energy, electrical impulses. VBLOC allows people with obesity to
take a positive path towards weight loss, addressing the lifelong
challenge of obesity and its comorbidities without sacrificing
wellbeing or comfort. EnteroMedics' Maestro Rechargeable System has
received CE Mark and is listed on the Australian Register of
Therapeutic Goods.  
Forward-Looking Safe Harbor Statement:  
This press release contains forward-looking statements about
EnteroMedics Inc. Our actual results could differ materially from
those discussed due to known and unknown risks, uncertainties and
other factors including our limited history of operations; our losses
since inception and for the foreseeable future; our lack of
commercial regulatory approval for our Maestro(R) System for the
treatment of obesity in the United States or in any foreign market
other than Australia and the European Community; our preliminary
findings from our EMPOWER(TM) and ReCharge pivotal trials; our
ability to comply with the Nasdaq continued listing requirements; our
ability to commercialize our Maestro System; our dependence on third
parties to initiate and perform our clinical trials; the need to
obtain regulatory approval for any modifications to our Maestro
System; physician adoption of our Maestro System and VBLOC(R) vagal
blocking therapy; our ability to obtain third party coding, coverage
or payment levels; ongoing regulatory compliance; our dependence on
third party manufacturers and suppliers; the successful development
of our sales and marketing capabilities; our ability to raise
additional capital when needed; international commercialization and
operation; our ability to attract and retain management and other
personnel and to manage our growth effectively; potential product
liability claims; potential healthcare fraud and abuse claims;
healthcare legislative reform; and our ability to obtain and maintain
intellectual property protection for our technology and products.
These and additional risks and uncertainties are described more fully
in the Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the annual
report on Form 10-K filed March 15, 2012. We are providing this
information as of the date of this press release and do not undertake
any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
Caution - Investigational device. Limited by Federal (United States)
law to investigational use.  
The implantation procedure and usage of the Maestro(R) System carry
some risks, such as the risks generally associated with laparoscopic
procedures and those related to treatment as described in the
ReCharge clinical trial informed consent.  
Company Contact:
EnteroMedics Inc.
Greg S. Lea
(651) 789-2860 
Media Contact:
Sam Brown Inc.
Mike Beyer
(312) 961-2502
Press spacebar to pause and continue. Press esc to stop.